

PRODNO = MDL-FOREM0002924
CD_NAME = MDLDVD001
TREATMENT : CONFIDENTIAL
FROM : Heydorn, William
TO : 'Mary Prescott'
DATE = 09/12/2002
TIME : 08:50:14 PM
SUBJECT : RE: citalopram
FOLDER : Outlook Folders\Personal Folders\Sent Mail July - Sept 2002
SOURCE : William Heydorn
MESSAGEID : <5604C2B45493FB40B30AE84F55529FFBA87CB2@mail-nyc1.frx2.com>
BODY : I'd go ahead and see if you can address Dr Findling's comments. Let me know if you need any information to answer his questions.

One point on the discussion - in paragraph 6, you need to remove/revise the statement about the lack of efficacy in children, since the results on that point have been pulled out.

Bill

-----Original Message-----

From: Mary Prescott [mailto:mary.prescott@prescottmedcom.com]

Sent: Wednesday, September 11, 2002 5:58 PM

To: Heydorn, William

Subject: FW: citalopram

That was quick! Dr. Findling has a few minor comments. Shall we wait until we hear back from Dr. Robb and then compile one final manuscript? Let me know. Thanks.

-----Original Message-----

From: Findling, Robert [mailto:Robert.Findling@uhhs.com]

Sent: Wednesday, September 11, 2002 4:30 PM

To: Mary Prescott

Subject: citalopram

Dear Mary:

Nice start.

Hope you find the comments constructive.

Thanks.

Bob

Robert L. Findling, M.D.
Director, Child & Adolescent Psychiatry

University Hospitals of Cleveland
Case Western Reserve University
11100 Euclid Avenue
Cleveland, Ohio 44106-5080
USA

PRODNO_MDL = MDL-FOREM0028429
CD_NAME : MDLCD021
TREATMENT : CONFIDENTIAL
FROM : Heydorn, William
TO : 'Mary Prescott'
MESSAGEID : <5604C2B45493FB40B30AE84F55529FFBA87CB2@mail-nyc1.frx2.com>
CC :
BCC :
DATE = 2002/09/12
TIME : 08:50:14 PM
SUBJECT : RE: citalopram
FOLDER : Outlook Folders\Personal Folders\Sent Mail July - Sept 2002
SOURCE : William Heydorn
ATTACHMENT :
BODY : I'd go ahead and see if you can address Dr Findling's comments. Let me know if you need any information to answer his questions.

One point on the discussion - in paragraph 6, you need to remove/revise the statement about the lack of efficacy in children, since the results on that point have been pulled out.

Bill

-----Original Message-----

From: Mary Prescott [mailto:mary.prescott@prescottmedcom.com]

Sent: Wednesday, September 11, 2002 5:58 PM

To: Heydorn, William

Subject: FW: citalopram

That was quick! Dr. Findling has a few minor comments. Shall we wait until we hear back from Dr. Robb and then compile one final manuscript? Let me know. Thanks.

-----Original Message-----

From: Findling, Robert [mailto:Robert.Findling@uhhs.com]

Sent: Wednesday, September 11, 2002 4:30 PM

To: Mary Prescott

Subject: citalopram

Dear Mary:

Nice start.

Hope you find the comments constructive.

Thanks.

Bob

Robert L. Findling, M.D.

Director, Child & Adolescent Psychiatry

University Hospitals of Cleveland

Case Western Reserve University

11100 Euclid Avenue

Cleveland, Ohio 44106-5080

USA